

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 January 2003 (03.01.2003)

PCT

(10) International Publication Number
WO 03/000672 A1

(51) International Patent Classification⁷: **C07D 307/87**

(21) International Application Number: PCT/DK02/00426

(22) International Filing Date: 25 June 2002 (25.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2001 00991 25 June 2001 (25.06.2001) DK

(71) Applicant (for all designated States except US): **H. LUNDBECK A/S** [DK/DK]; Ottiliavej 9, DK-2500 Valby-Copenhagen (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HUMBLE, Rikke, Eva** [DK/DK]; Æblevej 9, DK-2400 Copenhagen N (DK). **CHRISTENSEN, Troels, Volsgaard** [DK/DK]; Riffelhavevej 15, DK-4300 Holbæk (DK). **ROCK, Michael, Harold** [GB/DK]; Risbjergvej 28, DK-2650 Hvidovre (DK). **NIELSEN, Ole** [DK/DK]; Nystedvej 19, DK-2500 Valby (DK). **PETERSEN, Hans** [DK/DK]; Guldagervej 11, DK-2720 Vanløse (DK). **DANCER, Robert** [AU/DK]; J.M.Thielesvej 8, st th, DK-1961 Frederiksberg C (DK).

(81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM AND/OR S- OR R-CITALOPRAM BY SEPARATION OF A MIXTURE OF R- AND S-CITALOPRAM

(57) Abstract: The invention relates to a process for the preparation of racemic citalopram free base or an acid addition salt thereof and/or R- or S-citalopram as the free base or an acid addition salt thereof by separation of a mixture of R- and S-citalopram with more than 50% of one of the enantiomers into a fraction consisting of racemic citalopram and/or a fraction of S-citalopram or R-citalopram characterized in that i) citalopram is precipitated from a solvent as the free base or as an acid addition salt thereof; ii) the precipitate formed is separated from the mother liquor; iia) if the precipitate is crystalline it is optionally recrystallised one or more times to form racemic citalopram, and then optionally converted into an acid addition salt thereof; iib) if the precipitate is not crystalline, steps i) and ii) are optionally repeated until a crystalline precipitate is obtained and the crystalline precipitate is recrystallised one or more times to form racemic citalopram, and then optionally converted into an acid addition salt thereof; iii) the mother liquor is optionally subjected to further purification and S-citalopram or R-citalopram is isolated from the mother liquor and optionally converted into an acid addition salt thereof.

Process for the preparation of racemic citalopram and/or S- or R-citalopram by separation of a mixture of R-and S-citalopram

The invention relates to a process for the preparation of racemic citalopram and/or S-
5 or R-citalopram by separation of a mixture of R- and S-citalopram with more than 50
% of one of the enantiomers into; a fraction of racemic citalopram and/or a fraction of
S-citalopram or R-citalopram containing low amounts of the other enantiomer. The
invention also relates to a process for the preparation of racemic as well as
enantiomerically pure citalopram from the compound R-4-[4-(dimethylamino)-1-(4'-
10 fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile.

Background of the invention

S-citalopram (escitalopram) is the active component of the product citalopram, which
15 is a racemic mixture of the R- and S- enantiomers. The compound is a valuable
antidepressant of the selective serotonin reuptake inhibitor (SSRI) type.

Both racemic citalopram and S-citalopram are marketed as antidepressant agents.

20 It has now surprisingly been found that a mixture of R- and S-citalopram containing
more than 50 % of one of the enantiomers, i.e a non-racemic mixture, may be
separated into a fraction of racemic citalopram and a fraction of S- or R-citalopram by
precipitation of citalopram as the free base or as an acid addition salt thereof. The
surplus of S-citalopram or R-citalopram may be isolated from the mother liquor of
25 the precipitation.

This is an important and very useful process, in particular because it allows the
preparation of racemic citalopram and S-citalopram from mixtures of R- and S-
citalopram obtained from manufacturing processes which result in mixtures which do
30 not meet the specifications of the marketing approval of neither racemic citalopram
nor S-citalopram (in escitalopram, the amount of R-citalopram compared to S-
citalopram should be less than 3 %, preferably less).

S-citalopram may be prepared by separation of the R- and S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (the R- and S-diol) followed by ring closure of the S-diol with retention of configuration, as described in EP-B1-347 066.

5

Other processes for the preparation of S-citalopram including chromatographic separation of enantiomers are also available. It is for example possible to separate the corresponding bromo-derivative, 1-(4-Bromo-2-hydroxymethylphenyl)-4-dimethylamino-1-(4-fluorophenyl)butan-1-ol from the corresponding R-diol, followed
10 by ring closure with retention of configuration and cyanation to form S-citalopram. Cyanation processes for citalopram are well known and have been described in US 4.136.193, WO 00/11926 and WO 00/13648.

Depending on the specific process used and the conditions used, the enantiomeric
15 purity of the S-citalopram product obtained may have to be improved.


Other processes for stereo-selective synthesis of S-citalopram may also result in mixtures of R-and S-citalopram which do not fulfil the specifications of the marketing approval of S-citalopram.

20

Thus, according to one aspect of the invention, the invention provides an easy way to improve the enantiomeric purity of S-citalopram obtained by such processes.

During the production of S-citalopram by chromatographic separation of R- and S-4-
25 [4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile followed by ring closure of S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile, the R-enantiomer of formula (I)

3



I

is formed as a by-product.

5

It has now been found that ring closure of a compound of formula I in an acidic environment provides a reaction mixture containing a surplus of S-citalopram compared to R-citalopram. In other words, ring closure in an acidic environment proceed with partial inversion of configuration.

10

Accordingly, the by-product of formula (I) may be used for the preparation of S-citalopram and racemic citalopram and the method for the production of S-citalopram has thereby become more rational and more economical in the utilisation of reagents and resources.

15

Summary of the Invention

Thus, the present invention relates to a process for the preparation of racemic citalopram free base or an acid addition salt thereof and/or R- or S-citalopram as the free base or an acid addition salt thereof by separation of a mixture of R- and S-citalopram with more than 50 % of one of the enantiomers into a fraction consisting of racemic citalopram and/or a fraction of S-citalopram or R-citalopram **characterized in that**

25

- i) citalopram is precipitated from a solvent as the free base or as an acid addition salt thereof;

- ii) the precipitate formed is separated from the mother liquor;
 - 5 iia) if the precipitate is crystalline it is optionally recrystallised one or more times to form racemic citalopram, and then optionally converted into an acid addition salt thereof;
 - iib) if the precipitate is not crystalline, steps i) and ii) are optionally repeated until a crystalline precipitate is obtained and the crystalline precipitate is optionally recrystallised one or more
10 times to form racemic citalopram, and then optionally converted into an acid addition salt thereof;
 - iii) the mother liquor is optionally subjected to further purification and S-citalopram or R-citalopram is isolated from the mother liquor and
15 optionally converted into an acid addition salt thereof.

20 According to one specific embodiment, the invention relates to a method for the preparation of racemic citalopram free base or an acid addition salt thereof using the process described above.

According to another specific embodiment, the invention relates to a method for the preparation of R- or S-citalopram free base or an acid addition salt thereof using the process described above.

25 The acid used for precipitation of a citalopram salt in step i) is an acid which may precipitate a mixture of R- and S-enantiomer and leave the mother liquor enriched with either the S- or R- enantiomer of citalopram. One such acid is hydrobromic acid.

30 According to a preferred embodiment of the invention, the free base of citalopram or the hydrobromide salt of citalopram is precipitated, preferably in crystalline form in steps i) and ii).

According to another embodiment of the invention, the mixture of R- and S-citalopram used in step i) contains more than 50 % of S-citalopram, or more preferred more than 90 % of S-citalopram.

5 In step iii) S-citalopram (or R-citalopram) may be isolated from the mother liquor by the evaporation of the mother liquor and thereafter optionally the conversion of S-citalopram (or R-citalopram) into an acid addition salt thereof, preferably the oxalate salt.

10 Alternatively, if the mother liquor obtained from the precipitation is acidic, S-citalopram (or R-citalopram) may be isolated from the mother liquor by basifying the mother liquor, followed by phase separation, or extraction with a solvent and evaporation of the solvent, and thereafter optionally conversion of S-citalopram (or R-citalopram) into an acid addition salt thereof, preferably the oxalate salt.

15

The mother liquor, extracts thereof, or the phase containing R- or S-citalopram may be subjected to conventional purification processes (such as treatment with active carbon, chromatography, etc.) and/or it may be subjected to further precipitations as in step i)-ii) above before R- or S-citalopram is isolated.

20

The mixture of R- and S-citalopram with more than 50 % of the S-enantiomer may be prepared from a mixture of R- and S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile with more than 50% of the S-enantiomer by formation of a labile ester group and thereafter ring closure in a basic environment.

25

In another embodiment of the invention, the mixture of R- and S-citalopram with more than 50 % of the R-enantiomer is prepared from a mixture of R- and S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile with more than 50% of the R-enantiomer by formation of a labile ester group and thereafter ring closure in a basic environment.

30

In a further embodiment of the invention, the mixture of R- and S-citalopram with more than 50 % of the S-enantiomer is prepared from a mixture of R- and S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile with more than 50% of the R-enantiomer by ring closure in presence of an acid.

In still a further embodiment of the invention, the mixture of R- and S-citalopram with more than 50 % of the R-enantiomer is prepared from a mixture of R- and S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile with more than 50% of the S-enantiomer by ring closure in presence of an acid.

Preferably, the enantiomeric purity of the starting material R-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile is more than 90 %.

The acid used in the acidic ring closure reaction may suitably be a mineral acid such as H_2SO_4 or H_3PO_4 , a carboxylic acid, a sulfonic acid or a sulfonic acid derivative.

Whenever used in this document, racemic mixture or racemic citalopram means a 1:1 mixture of R- and S-citalopram. Non-racemic mixtures or non-racemic citalopram means mixtures which do not contain R- and S-citalopram as a 1:1 mixture.

Citalopram means a mixture of R- and S-citalopram. Citalopram enantiomer or isomer means either S- or R-citalopram.

As used in this description, precipitation means forming a precipitate in the form of crystals, an amorphous solid or an oil from a solvent. In the present description, a precipitate means an oil, an amorphous solid or crystals.

As used herein, mother liquor means the solvent remaining after removal or separation from the precipitate.

Detailed description of the invention

As mentioned above processes for the preparation of the citalopram molecule may
5 result in a mixture of R- and S-citalopram which is not acceptable for pharmaceutical
use. According to the invention, a surprisingly efficient process for the separation of
such mixtures into a racemic fraction and a fraction of S-citalopram or R-citalopram
has been found. This new process involves precipitation of citalopram free base or an
acid addition salt thereof as an oil, an amorphous solid or in crystalline form from a
10 solvent, and isolation of S-citalopram (or R-citalopram) from the mother liquor of the
precipitation process.

The precipitation of the citalopram free base may be carried out by obtaining or
dissolving the non-racemic mixture of R- and S-citalopram in a suitable solvent,
15 optionally by applying heating, and then allowing the solution to cool. The precipitate
is then separated from the mother liquor, preferably by filtration or decanting. If the
precipitate is crystalline, the crystals are optionally recrystallised and the free base of
racemic citalopram may then be converted to a salt thereof, preferably the
hydrobromide salt.

20 If the precipitate formed is an oil or an amorphous solid, the precipitation process may
be repeated until a crystalline product is obtained. The crystals obtained are
optionally recrystallised and the free base of racemic citalopram may then be
converted to a salt thereof, preferably the hydrobromide salt.

25 Depending on the ratio of R- and S-citalopram in the starting material, it may be
necessary to precipitate (in particular crystallise) citalopram free base more than once
in order to obtain racemic citalopram. The mother liquors from each precipitation
may be pooled together and the citalopram enantiomer contained herein may be
30 isolated as described below.

Suitable solvents for the precipitation of the citalopram free base are alkanes, such as
heptane or hexane, alcohols, such as isopropanol, aromatic compounds such as

toluene, benzene and xylene, or mixtures of alcohol and water and mixture of alkanes and alcohols. Thus, both aprotic and protic solvent may be useful.

If necessary crystallisation may be initiated by seeding with racemic crystalline
5 citalopram base.

The precipitation of an acid addition salt of citalopram may be carried out by obtaining or dissolving the non-racemic mixture of R- and S-citalopram in a suitable solvent, if necessary by applying heating, and then adding an acid, either in a solution
10 or as a gas. If crystals are formed, the crystals are separated from the mother liquor, preferably by filtration. The crystals are optionally re-crystallised by dissolving the crystals in a solvent, preferably by heating, and allowing the solution to cool.

If the precipitate formed is not crystalline, but amorphous or an oil, the precipitation
15 process may be repeated until a crystalline product is obtained. The crystals obtained are optionally recrystallised as described above and the racemic citalopram salt may optionally be converted into another salt thereof.

Depending on the ratio of R- and S-citalopram in the starting material, it may be
20 necessary to precipitate (in particular crystallise) the citalopram salt more than once in order to obtain a racemic mixture. The mother liquors from each precipitation or crystallisation may be pooled together and the citalopram enantiomer contained herein may be isolated as described below.

25 The acid used for precipitation of a citalopram salt is an acid which may precipitate a mixture of R- and S-enantiomer and leave the mother liquor enriched with either the S- or R- enantiomer of citalopram. One such acid is hydrobromic acid.

Suitable solvents for the precipitation and recrystallisation of citalopram salts are
30 protic solvents such as water, alcohols such as methanol and ethanol, ketones such as acetone, and mixtures thereof or aprotic solvent such as acetonitrile or diglyme.

If necessary crystallisation may be initiated by seeding with the racemic crystalline citalopram salt.

Crystallisation of the free base or the hydrobromide salt of citalopram is preferred.

5

S-citalopram (or R-citalopram) may be isolated from the mother liquor using conventional procedures such as by evaporation of the solvent from the mother liquor, or in case the mother liquor is acidic by basifying followed by separation of phases (if it is an oil) or by extracting S-citalopram (or R-citalopram) followed by evaporation of the solvent. S-citalopram (or R-citalopram) may then be converted to a salt thereof, preferably the oxalate salt and optionally re-crystallised.

10

The mother liquor or extracts thereof may be subjected to conventional purification processes before evaporation of the solvent, or it may be subjected to one or more precipitations of citalopram free base or citalopram salt according to the invention, in order to improve the enantiomeric purity of the citalopram enantiomer product.

15


Likewise, an oily phase separated from the mother liquor may be subjected to conventional purification processes, or it may be subjected to one or more precipitations of citalopram free base or citalopram salt according to the invention, in order to improve the enantiomeric purity of the citalopram enantiomer product.

20

In another aspect of the invention it has been found that ring closure of the by-product of formula I in an acidic environment provides a reaction mixture containing a surplus of the S-enantiomer.

25

The process is illustrated in the reaction scheme below:



- 5 When the reaction is performed in the presence of an acid, a mixture of R-citalopram and S-citalopram is obtained from R-diol. The stereochemistry in this reaction is partly inverted, resulting in surplus of S-citalopram. The surplus amount of S-citalopram relative to R-citalopram is dependent upon the S/R ratio of the starting material as demonstrated below. The ratio of inversion versus retention is around
- 10 70:30 to 75:25 dependent on the reaction conditions of the experiment.

A surplus of S-citalopram will exist if an 4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile with more than 50 % of the R-enantiomer is used as the starting material. This resulting mixture can be further

15 purified to give an S/R ratio of more than 95/5 by precipitation of the citalopram base from a solvent or by precipitation as an acid addition salt of citalopram from a solvent. A pure S-citalopram (S/R ratio more than 97/3) may be isolated from the mother liquor, and precipitated as an acid addition salt with an acid, such as oxalic acid.

- As mentioned above, the stereochemistry is partly inverted when the ring closure of R- and S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile is carried out in an acidic environment. Any suitable acid may be useful for this ring closure reaction. Good results were obtained with mineral acids such as sulphuric acid, HCl and phosphoric acid, and organic acids such as p-toluenesulphonic acid. In a preferred embodiment of the invention, sulphuric acid is used. Preferably, surplus amount of acid relative to starting material should be used.
- 10 The reaction can be performed in organic solvents suitable for dissolving the starting materials. Preferred solvents are solvents suitable for large-scale chemical production. Good results were obtained using toluene or acetonitrile.

- When ring closure of the starting material of formula (I) is performed via a labile ester intermediate, ie. in the presence of tosyl-chloride, in a basic environment, as described in EP-B1-347 066, the ring closing reaction proceeds with retention of the stereochemistry. The R-form of citalopram in an enantiomeric purity substantially equal to the starting material is then obtained.

- 20 This, thus-obtained R-form of citalopram can be optionally mixed with a mixture of R and S-citalopram with an S-citalopram surplus to obtain racemic citalopram. Racemic citalopram may be obtained by one or more precipitations of citalopram free base or a salt thereof, followed by recrystallisation as described above.

25 Examples

In the following examples optical purity is measured by Chiral HPLC.

Example 1**Preparation of Citalopram from R-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (R/S ratio: 95,7/4,3) by reaction with different acids in acetonitrile**

General method:

R-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (67.5 g, R/S ratio: 95,7/4,3) dissolved in acetonitrile (37g) was stirred at room temperature, and a mixture of acid and ice (or water) was added (the quantity of acid and ice are listed in Table 1). The mixture was stirred at 78-85 °C (the reaction time have been listed in Table 1). The reaction mixture was cooled and water and toluene (315 mL) were added. Aqueous ammonia (25% by weight) was added to give a pH 9.5-10.5 and the mixture was heated to 50-55 °C (5-10 minutes). The phases were separated and to the water phase was added toluene (50 mL), and the phases was stirred at 50-55 °C (5-10 minutes). The phases were separated and the combined toluene phases were washed three times with water (3 x 65 mL). The toluene was removed at reduced pressure at a maximum of 60 °C to give the product as an oil.

Citalopram was prepared by the general method above. The type of acid and the quantities of acid and ice (water) in the acid mixture are listed in Table 1. The percentage of the citalopram that is S-citalopram, analysed by chiral HPLC, is listed in Table 1 as well.

Example	Acid type	Mass of acid	Mass of ice or water in mixture	Reaction time	Percent S-citalopram	Yield
1	Sulphuric acid	25 g	10 g ice	3 hours	73.4	65.6 g (~100%)
2	Sulphuric acid	87 g	35 g ice	3 hours	72.0	57.0 g (89%)
3	Hydrochloric acid	22 g	11 g ice	24 hours	> 65	64.6 g (~100%)
4	p-Toluenesulfonic acid	43 g	40 g water	48 hours	73.0	61.6 g (95%)

Table 1. Citalopram by reaction with different acids in acetonitrile.

Example 2

5

Preparation of Citalopram from R-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (R/S ratio: 95,7/4,3) by reaction with different acids in toluene.

10 General method: R-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (67.5 g, R/S ratio: 95,7/4,3) was dissolved in toluene (315 mL). At room temperature, a mixture of acid and ice (or water) was added (the quantities of acid and ice are listed in Table 2). The mixture was stirred at 78-85 °C (the reaction time have been listed in Table 2). The reaction mixture was cooled and
15 water was added. Aqueous ammonia (25% by weight) was added to give a pH 9.5-10.5. The mixture was heated to 50-55 °C (5-10 minutes). The phases were separated and the toluene phase was washed three times with water (3 x 65 mL). The toluene was removed at reduced pressure at a maximum of 60 °C. The product was an oil.

20 Citalopram was prepared by the general method above. The type of acid and the quantities of acid and water in the mixture are listed in Table 2. The percentage of the citalopram that is S-citalopram, analysed by chiral HPLC, is listed in Table 2 as well.

Example	Acid type	Mass of acid	Mass of ice or water in mixture	Reaction time	Percent S-Citalopram	Yield
5	Sulphuric acid	26 g	10 g ice	70 minutes	73.8	61.8 g (97%)
6	Phosphoric acid	275 g	11 g ice	4 hours	70.9	67.2 g (~100%)

Table 2. Citalopram by reaction with different acids in toluene.

25

Example 3

Preparation of Citalopram HBr (racemic) from R-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (R/S ratio: 95,7/4,3) by combination of products obtained from the acidic and the basic ring-closure methods.

5

Acidic ring closure:

R-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (67.5 g, R/S ratio: 95,7/4,3) was dissolved in toluene (315 mL). At room temperature, a mixture of sulphuric acid (26 g, 96%) and ice (10 g) was added. The mixture was stirred at 78-85 °C for 2 hours. The reaction mixture was cooled and 40 mL water was added. Aqueous ammonia (25% by weight) was added to give a pH 9.5-10.0. The mixture was heated to 55 °C (10 minutes). The phases were separated and the toluene phase was washed three times with water (3 x 65 mL). The toluene was removed at reduced pressure at a maximum of 60 °C to give an oil (oil A). Yield: 63 g (99%).

15

Basic ring closure of labile ester:

R-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (33.7 g, R/S ratio: 95,7/4,3) was dissolved in acetonitrile (16 g) and toluene (135 mL). 21.4 g Triethylamin was added. A solution of tosylchlorid (19.7 g) and toluene (55 mL) was added to the mixture at a rate so that the temperature was kept below 50 °C. The mixture was stirred at 10 °C for 20 minutes. Water (75 mL) was added and the mixture was stirred for 5 minutes. Aqueous ammonia (25% by weight) was added to give a pH of 9.5. The phases were separated and toluene (35 mL) was added to the water phase. This was stirred for 10 minutes at 45 °C. The toluene phases were combined and washed with water (2 x 75 mL). The toluene was removed at reduced pressure at a maximum of 50 °C to give an oil (oil B). Yield: 32.3 g (~100%).

20

25

Precipitation of a mixture of oils A and B.

30

Oil A (57 g) and oil B (28 g) were mixed by dissolving in acetone (310 mL) at room temperature. 35 mL of the solution was removed, HPLC showed an S/R ratio of 49.6/50.4. The mixture was cooled. The pH was 3-4.5. 15 mL of the solution were

removed before addition of hydrogen bromide. Gaseous hydrogen bromide was added until pH was 1.5. The mixture was cooled to 15 °C and stirred overnight. The crystals were filtered and washed with a mixture of acetone (70 mL) and hexane (70 mL).

After drying, a yield of 75.7 g (71%) crystals was obtained. The purity of the crystals
5 was 99.2% (HPLC) and the S/R ratio was 49.5/50.5 (Chiral HPLC).

Recrystallisation in water

Crystals (29.9 g) from the precipitation of oils A and B were dissolved in 75 mL water at about 48 °C. The solution was cooled and seeded, and it was stirred for 2½ day at
10 room temperature. The mixture was cooled to 8 °C. The crystals were filtered off and washed with water (24 mL). After drying, a yield of 27.9 g (93.3%) Citalopram HBr (racemic) was obtained. The purity of the crystals was 99.4% (HPLC) and the S/R ratio was 50/50% (Chiral HPLC), hence a racemic substance was obtained.

15 Example 4

Preparation of S-citalopram oxalate from R-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (R/S ratio: 95,7/4,3).

20

Ring closure in presence of sulphuric acid

R-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (67.0 g, R/S ratio: 95,7/4,3%) was dissolved in toluene (315 mL). At room temperature, a mixture of sulphuric acid (25 g, 96%) and ice (10 g) was added.
25 The mixture was stirred at 80-85 °C for 1 hour and 40 minutes. The reaction mixture was cooled to room temperature and water (40 mL) was added. Aqueous ammonia (50 mL, 25% w/w) was added to adjust pH to 10.5. The mixture was heated to 55°C (10 minutes). The phases were separated and the toluene phase was washed three times with water (3 x 65 mL). The toluene was removed at reduced pressure at a
30 maximum of 60 °C to an oil. Yield: 60.4 g (95%).

The oil (60.4 g) was dissolved in heptane (600 mL) by heating to 89 °C. The mixture was allowed to cool to room temperature and stirred over-night. The mixture was filtered. The mother liquor was evaporated and the yield was 20.4 g (34%).

The mother liquor was dissolved in ethanol (78 mL) and the mixture was cooled to
5 <25 °C. A solution of oxalic acid anhydrate (10.2 g) in ethanol (48 mL) was added. The mixture was stirred for 3 hours at < 15 °C. The mixture was filtered and washed with ethanol (24 mL). After drying, a yield of 19.9 g (76%) was obtained. The purity of the crystals was 96.8% (HPLC) and the S/R ratio was 97,6/2,4 (Chiral HPLC).

10 Example 5

Preparation of Citalopram from R-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (R/S ratio: 69,0/31,0) by reaction with sulphuric acid in acetonitrile.

15 R-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (31.1 g, R/S ratio: 69,0/31,0) dissolved in acetonitrile (420 g) was stirred at room temperature and a mixture of sulphuric acid (50 g, 96%) and ice (17 g) was added. The mixture was stirred at 78-80 °C for 1 hour. The reaction mixture was
20 cooled and water and toluene (160 mL) were added. Aqueous ammonia (25% by weight) was added to give a pH of 10.5. The mixture was heated to 50-55 °C (5-10 minutes). The phases were separated and to the water phase was added toluene (25 mL) and it was stirred at 50-55 °C (5-10 minutes). The phases were separated and the combined toluene phases were washed three times with water (3 x 50 mL). The
25 toluene was removed at reduced pressure at a maximum of 60 °C. The product was an oil. Yield: 32.9 g (90%). The purity of the evaporated mother liquor was 96.9% and the S/R ratio was 59.5/40.5 (Chiral HPLC).

Example 6

Preparation of Citalopram from S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (S/R ratio: 99,1/0,9) by reaction
5 **with sulphuric acid in toluene.**

S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (67.0 g, S/R ratio: 99,1/0,9) was dissolved in toluene (315 mL). At room temperature a mixture of sulphuric acid (25.8 g, 96% and ice (10.7 g) was added. The
10 mixture was stirred at 78-85 °C for 2 hours. The reaction mixture was cooled and water (40 mL) was added. Aqueous ammonia (50 mL, 25% by weight) was added to give a pH 10.5-11.0. The mixture was heated to 57°C (10 minutes). The phases were separated and the toluene phase was washed three times with water (3 x 65 mL). The toluene was removed at reduced pressure at a maximum of 60 °C. The product was an
15 oil. Yield: 63.9 g (~100%). The purity of the oil was 94.9% and the S/R ratio was 26.3/73.7 (Chiral HPLC).

Example 7

20 Purification of *S*-citalopram by precipitation of the free base

Precipitation experiments were conducted to determine how efficient the process was for the removal of small amounts of mixtures *R*- and *S*-citalopram from *S*-citalopram. See Table 3 for the results. The general procedure was as follows. To a mixture of *S*-
25 and *R*-citalopram (as described in the "Before precipitation" column) was added heptane (10 mL/ 1 g citalopram). The mixtures were warmed to reflux, whereupon the citalopram samples dissolved. Heating was stopped, and the samples were allowed to cool to room temperature slowly. In all cases, some material fell out of solution. Where there was a large amount of the *R*-citalopram in the starting material, the
30 residue was generally a solid, but where there was only a small amount of the *R*-citalopram in the starting material, the residue was generally an oil. In all cases the mother liquor was removed by filtration (or decanting, in the case of an oily precipitate). The *R/S* ratios of the precipitates are shown in Table 3. The filtrates were

evaporated to give oils/amorphous solids. The R/S ratios of these oils/amorphous solids are shown in the columns "Oil/amorphous solid after evaporation" in Table 3.

- 5 In all cases, the products were analysed by chiral SCFC HPLC.

Before Precipitation		After Precipitation			
Mixture of Isomers		Precipitate (mixture of R and S-citalopram)		Oil/amorphous solid after evaporation (enriched S-enantiomer)	
S%	R%	S%	R%	S%	R%
98,2	1,8	99	1,3	98,1	1,9
97,5	2,5	98	2,5	96,9	3,1
95,4	4,6	82	17,6	98,8	1,2
94,2	5,8	66	34	98,5	1,5
89,0	11	65	35	98,5	1,5
80,3	19,7	54	46	98,4	1,6
61,0	39	53	47	96,7	3,3

Table 3: Precipitation of the free racemic citalopram base

- Inspection of the last 5 rows in Table 3 shows that when the ratio S/R in the starting material is less than 97/3, a substantial enrichment of the S-isomer occurs in the oil after evaporation of the filtrate. In all cases, the ratio of S/R in the final product is > 95/5.

Example 8

15

Purification of S-citalopram by precipitation of citalopram as the hydrobromide salt

- A mixture of citalopram isomers was dissolved in *iso*-propyl alcohol (IPA) (10 ml IPA / 1 g citalopram). A solution of anhydrous HBr in IPA (2,0 eq, 5,2 M) was added dropwise, and the solutions were seeded with racemic citalopram HBr crystals. The solutions were stirred overnight and filtered. The filtrate was evaporated to give an oil/amorphous solid. The results of these experiments are shown in Table 4. "Before Precipitation" refers to the composition of the mixture before addition of HBr, and

“After Precipitation” refers to the two products isolated after filtration. No crystalline material was isolated in the first case (where the “Mixture of Isomers” was S: 98,2% and R: 1,8%). The products were analysed by chiral SCFC HPLC.

Before Precipitation		After Precipitation			
Mixture of Isomers		Crystalline solid from IPA (mixture of R and S-citalopram)		Oil after evaporation of IPA (enriched S-citalopram)	
S%	R%	S%	R%	S%	R%
98,2	1,8			98,7	1,3
97,5	2,5	75	25	> 99,9	< 0,1
95,4	4,6	69	31	> 99,9	< 0,1
94,2	5,8	68	32	> 99,9	< 0,1
89,0	11	69	31	> 99,9	< 0,1
78,7	21,3	65	35	98,9	1,1
80,3	19,7	60	40	98,4	1,6
61,0	39	56	44	96,7	3,3

5 Table 4: Crystallisation of citalopram HBr salt

In almost all cases, there was virtually no *R*-isomer remaining in the mother liquor, and the yield of the precipitates and the oils after evaporation reflect this. Inspection of the first column and the second last column indicates that in most cases, substantial enrichment of the *S*-isomer occurred, and that in all cases the S/R ratio of the oil after evaporation was greater than 96/4.

Claims:

1. A process for the preparation of racemic citalopram free base or an acid addition salt thereof and/or R- or S-citalopram as the free base or an acid addition salt thereof by separation of a mixture of R- and S-citalopram with more than 50 % of one of the enantiomers into a fraction consisting of racemic citalopram and/or a fraction of S-citalopram or R-citalopram **characterized in that**
- i) citalopram is precipitated from a solvent as the free base or as an acid addition salt thereof;
 - ii) the precipitate formed is separated from the mother liquor;
 - 15 iia) if the precipitate is crystalline it is optionally recrystallised one or more times to form racemic citalopram, and then optionally converted into an acid addition salt thereof;
 - 20 iib) if the precipitate is not crystalline, steps i) and ii) are optionally repeated until a crystalline precipitate is obtained and the crystalline precipitate is optionally recrystallised one or more times to form racemic citalopram, and then optionally converted into an acid addition salt thereof;
 - 25 iii) the mother liquor is optionally subjected to further purification and S-citalopram or R-citalopram is isolated from the mother liquor and optionally converted into an acid addition salt thereof.
2. A process according to claim 1 for the preparation of S-citalopram or R-citalopram **characterized in that**
- 30 i) citalopram in the mixture of R- and S-citalopram is precipitated from a solvent as the free base or as an acid addition salt thereof;

- ii) the precipitate formed is separated from the mother liquor, and
- iii) the mother liquor is optionally subjected to further purification and S-citalopram or R-citalopram is isolated from the mother liquor and
5 optionally converted into an acid addition salt thereof.

3. A process according to claim 1 for the preparation of racemic citalopram
characterized in that

- 10 i) citalopram in the mixture of R- and S-citalopram is precipitated from a solvent as the free base or as an acid addition salt thereof;
- ii) the precipitate formed is separated from the mother liquor,
 - 15 iia) if the precipitate is crystalline it is optionally recrystallised one or more times to form racemic citalopram, and then optionally converted into an acid addition salt thereof;
 - iib) if the precipitate is not crystalline, steps i) and ii) are repeated
20 until a crystalline precipitate is obtained and the crystalline precipitate is optionally recrystallised one or more times to form racemic citalopram, and optionally converted into an acid addition salt thereof.

25 4. The method according to claims 1-3 **characterized in that** the acid used for precipitation of citalopram in step i) is an acid which precipitate a mixture of R- and S-enantiomer and leave the mother liquor enriched with either the S- or R- enantiomer of citalopram.

30 5. The process according to claims 1-4 wherein the salt precipitated in in step i) is the hydrobromide salt, preferably in crystalline form.

6. The process according to claims 1-3 wherein the free base is precipitated in step i).
7. The process according to claims 1-3 **characterised in that** the mixture of R- and S- citalopram with more than 50 % of one of the enantiomers contain more than 50 % of S-citalopram, or more preferred more than 90 % of S-citalopram.
8. The process according to claims 1-2 or 4-7 **characterised in that** S-citalopram is isolated from the mother liquor by evaporation and thereafter optionally converted to an acid addition salt thereof, preferably the oxalate salt.
9. The process according to claims 1-2 or 4-7 **characterised in that** the mother liquor is acidic and S-citalopram is isolated from the mother liquor by basifying the mother liquor, followed by phase separation or extraction with a solvent and evaporation of the solvent, and thereafter optionally conversion of S-citalopram into an acid addition salt thereof, preferably the oxalate salt.
10. The process of claims 1-2 or 4-9 wherein the mother liquor is subjected to one or more further precipitations of citalopram as described under step i) before isolation of the R- or S-citalopram from the mother liquor.
11. The process according to claims 1-9 **characterised in that** a mixture of R- and S-citalopram with more than 50 % of the S-enantiomer is prepared from a mixture of R- and S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile with more than 50% of the S-enantiomer by formation of a labile ester group and thereafter ring closure in a basic environment.
12. The process according to claims 1-6 and 8-9 **characterised in that** a mixture of R- and S-citalopram with more than 50 % of the R-enantiomer is prepared from a mixture of R- and S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile with more than 50% of the R-enantiomer by formation of a labile ester group and thereafter ring closure in a basic environment.

13. The process according to claims 1-9 **characterised in that** a mixture of R- and S-citalopram with more than 50 % of the S-enantiomer is prepared from a mixture of R- and S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile with more than 50% of the R-enantiomer by ring closure in presence of an acid.
14. The process according to claims 1-6 and 8-9 **characterised in that** mixture of R- and S-citalopram with more than 50 % of the R-enantiomer is prepared from a mixture of R- and S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile with more than 50% of the S-enantiomer by ring closure in presence of an acid.
15. A process for the preparation of a mixture of R- and S citalopram with more than 50 % of the S-enantiomer **characterised in that** a mixture of R- and S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile with more than 50% of the R-enantiomer is subjected to ring closure in presence of an acid.
16. A process for the preparation of a mixture of R- and S-citalopram with more than 50 % of the R-enantiomer **characterised in that** a mixture of R- and S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile with more than 50% of the S-enantiomer is subjected to ring closure in presence of an acid.
17. The process according to claims 12, 13 or 15 **characterised in that** the starting material contain more than 90% of R-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile compared to S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile.
18. The process according to claims 13-16 **characterised in that** the acid used in the ring-closure reaction is a mineral acid, a carboxylic acid, a sulfonic acid or sulfonic acid derivative.

5

19. The process according to claim 18 **characterised in that** the acid is H_2SO_4 or H_3PO_4 .

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 02/00426

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 307/87

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0347066 A1 (H. LUNDBECK A/S), 20 December 1989 (20.12.89) -- -----	1-20

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

13 November 2002

Date of mailing of the international search report

15-11-2002

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Göran Karlsson/BS
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK02/00426

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see next sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

As is stated in Annex B to Administrative Instructions under the PCT, in force July 1, 1998, (PCT GAZETTE 1998, June 25, pp 45-50) unity of invention exists only when there is a technical relationship among the claimed inventions involving one or more of the same or corresponding "special technical features"- i.e. features that define a contribution which each of the inventions makes over the prior art (cf. PCT Rule 13.2). It is well known to a person skilled in the art, that compounds with 5-HT₄ receptor agonist activity have pharmaceutical use. This leads to the presence of the subjects listed below, each falling under its own restricted inventive concept.

Invention 1. A process according to claims 1-14 involving precipitation of citalopram from a solvent.

Invention 2. A process according to claims 15-20 involving a ring-closure reaction.

INTERNATIONAL SEARCH REPORT

Information on patent family members

28/10/02

International application No.

PCT/DK 02/00426

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
EP	0347066	A1	20/12/89	SE	0347066 T3	
				AT	119896 T	15/04/95
				AU	623144 B	07/05/92
				AU	3629589 A	04/01/90
				CA	1339568 A	02/12/97
				CY	2081 A	16/10/98
				DE	68921672 D,T	27/07/95
				DK	11593 A	01/02/93
				DK	170280 B	24/07/95
				DK	259989 A	15/12/89
				ES	2068891 T	01/05/95
				FI	91527 B,C	31/03/94
				FI	98627 B,C	15/04/97
				FI	892823 A	15/12/89
				FI	941829 A	20/04/94
				FI	20000507 A	06/03/00
				GB	8814057 D	00/00/00
				GR	3015889 T	31/07/95
				HK	139596 A	02/08/96
				HU	211460 B	28/11/95
				HU	9500496 A	28/09/95
				IE	65734 B,L	15/11/95
				IE	891859 L	14/12/89
				IL	90465 A	24/01/95
				JP	2036177 A	06/02/90
				JP	3038204 B	08/05/00
				JP	3044253 B	22/05/00
				JP	11292867 A	26/10/99
				MX	9203346 A	31/08/92
				NO	172892 B,C	14/06/93
				NO	892447 A	15/12/89
				NZ	229426 A	21/12/90
				PT	90845 A,B	29/12/89
				US	RE34712 E	30/08/94
				US	4943590 A	24/07/90
				ZA	8904476 A	25/04/90